Compare WT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WT | WVE |
|---|---|---|
| Founded | 1985 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 2011 | 2015 |
| Metric | WT | WVE |
|---|---|---|
| Price | $16.54 | $13.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | $17.08 | ★ $30.73 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 05-01-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 127.27 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $493,753,000.00 | $3,704,000.00 |
| Revenue This Year | $33.08 | $16.76 |
| Revenue Next Year | $7.39 | $149.85 |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | 15.43 | ★ 149.43 |
| 52 Week Low | $7.47 | $5.28 |
| 52 Week High | $17.68 | $21.73 |
| Indicator | WT | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 45.40 |
| Support Level | $15.38 | $12.53 |
| Resistance Level | $17.09 | $14.56 |
| Average True Range (ATR) | 0.66 | 0.78 |
| MACD | -0.09 | -0.02 |
| Stochastic Oscillator | 45.48 | 20.34 |
WisdomTree Inc is a financial innovator, offering a well-diversified suite of exchange-traded products (ETPs), models and solutions. It offers a broad range of ETFs and exchange-traded products (ETPs). The firm also engages in developing next-generation digital products and structures, including digital funds and tokenized assets, as well as its blockchain-native digital wallet, WisdomTree Prime. The Company conducts business under a single operating segment as an ETP sponsor and asset manager.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.